Scope and Claims Analysis of US Patent 12,180,219 (Crystalline Form of “Compound I-7”)

US Patent 12,180,219 protects specific solid-state, XRPD-defined crystalline forms of “Compound I-7,” with claim scope anchored to powder X-ray diffraction peak positions and variants that add further peaks, plus anhydrous status and downstream composition claims. The enforceable core is narrow and measurement-based: infringement turns on whether an accused material matches the claimed XRPD pattern (or the pattern-plus-peak limitations) closely enough in practice.

What is US Patent 12,180,219 and what does it protect?

Answer: It protects a crystalline form of “Compound I-7” defined by a powder XRPD pattern with specific 2θ peaks (notably ~5.5, 8.7, and 11.0), plus dependent claims that require additional peaks (~17.5 and/or ~22.7), specific XRPD pattern evidence (FIG. 2), anhydrous material, and a composition containing the crystalline form.

Patent claim structure and dependency map

The independent claim in your excerpt is effectively claim 1, with claims 2 to 5 narrowing the XRPD fingerprint, claim 6 narrowing water content, claim 7 tightening the fingerprint to include a full list of reflections/d-spacings, and claim 8 adding a composition layer.

Claim 1 (core crystalline form): XRPD pattern includes ~2θ peaks at about 5.5, 8.7, and 11.0
Claim 2: claim 1 + additional ~17.5 peak
Claim 3: claim 1 + additional ~22.7 peak
Claim 4: claim 1 + ~17.5 and ~22.7 peaks
Claim 5: claim 1 + XRPD pattern “as shown in FIG. 2”
Claim 6: claim 1 + anhydrous
Claim 7: claim 1 + XRPD pattern containing reflections/d-spacings at the enumerated list (full fingerprint)
Claim 8: composition comprising the crystalline form of claim 1

Protected “thing” in enforcement terms

This is a classic crystalline-form patent. The protected product is:

the crystalline polymorph/solvate form of Compound I-7, and
formulations/compositions containing that crystalline form (claim 8).

The patent does not (from the excerpt) protect:

amorphous forms,
other polymorphs/solvates not matching the listed XRPD fingerprint,
methods of making (no method claims shown in your excerpt),
uses (no method-of-use claims shown in your excerpt).

What are the exact XRPD limitations in claim 1 and how do they define infringement risk?

Answer: Claim 1 is infringed by a crystalline form of Compound I-7 whose powder XRPD pattern contains peaks at about 2θ ~5.5, ~8.7, and ~11.0. Risk depends on how an accused manufacturer’s XRPD measurement and peak fitting align with “about” tolerances and baseline/phase effects.

Claim 1 peak set (minimum required fingerprint)

~2θ 5.5
~2θ 8.7
~2θ 11.0

Those three reflections act as the minimum gate. Dependent claims expand the gate by requiring additional peaks (notably ~17.5 and/or ~22.7) or by requiring a fuller set.

How “about” affects practical claim scope

Because the claim uses “about,” the legal/technical fight usually becomes:

whether an accused XRPD pattern has peaks at sufficiently similar positions within the claim’s tolerance, and
whether extra peaks are allowed under the claim language (for example, claim 1 requires that the pattern comprises those peaks; it does not on its face exclude other peaks).

From a landscape perspective, this is a fingerprint-inclusion claim, not a “consisting of peaks” claim, at least based on the excerpt. That generally increases the chance of capturing materials that share the signature peaks but differ elsewhere, while still requiring the signature peaks.

Where claim 1 is likely to land on the scope spectrum

Narrow vs. broad: Narrow to the polymorph identity but broad across other minor differences because “comprising” can permit additional peaks.
Measurement sensitivity: High. XRPD patterns shift with:
- instrument calibration,
- sample prep and milling,
- particle size,
- humidity history (especially if other forms interconvert),
- preferred orientation and scan speed.

Which dependent claims add additional XRPD peaks and what do they change in scope?

Answer: Claims 2 to 4 add specific additional diagnostic peaks, tightening the pattern match and reducing ambiguity. Claims 5 and 7 tighten further by reference to FIG. 2 or by requiring an enumerated reflection/d-spacing list.

Claims 2–4: XRPD pattern expansions

Claim	Additional requirement beyond claim 1	Effect on scope
2	XRPD further comprises ~2θ 17.5	Captures materials with both the core triad and the 17.5 peak
3	XRPD further comprises ~2θ 22.7	Captures materials with the core triad and the 22.7 peak
4	XRPD further comprises ~2θ 17.5 and ~22.7	Most restrictive among these dependents

Claim 4 as the tightest “peak-combination” dependent claim

Claim 4 requires the core triad plus both ~17.5 and ~22.7. In infringement, this typically increases the probability that a non-identical polymorph avoids the claim by missing one of those peaks or shifting them outside “about” tolerance.

How does FIG. 2 language in claim 5 affect claim interpretation?

Answer: Claim 5 narrows to a crystalline form where the XRPD pattern is “as shown in FIG. 2.” This can function like a structural description: it ties infringement to the specific pattern image and its implied peak positions and intensities as presented in the patent.

Practical impact

FIG.-based claim language can reduce argument space about which peaks are required, because the patentee can point to:

the set of peaks shown,
their relative positions,
and sometimes their relative intensities.

However, it also creates litigation work for both sides:

accused infringers can argue that their pattern matches by position but differs in intensity or background,
plaintiffs argue the pattern “as shown” means the full pattern behavior.

What does the anhydrous limitation in claim 6 mean for polymorph/solvate competitors?

Answer: Claim 6 restricts the claimed crystalline form to anhydrous material. This narrows infringement away from hydrates/solvates, even if XRPD signatures partly overlap.

Landscape consequence

If Compound I-7 has:

multiple crystalline phases,
hydrates/solvates with partially overlapping peaks, or
forms that dehydrate on drying,

then claim 6 can become a key differentiator. A competitor can attempt to route around by marketing/manufacturing a hydrate/solvate that does not meet the anhydrous characterization requirement, or by demonstrating that the marketed solid is not anhydrous under relevant conditions.

Enforcement angle

Even when XRPD patterns resemble an anhydrous polymorph, demonstrating anhydrous status typically relies on:

Karl Fischer,
thermogravimetric analysis (TGA),
controlled humidity studies,
or spectroscopy evidence. The claim language itself places the characterization burden in scope definition.

How strong is claim 7’s full reflection/d-spacing list, and what does it cover?

Answer: Claim 7 is the tightest XRPD fingerprint claim in your excerpt because it enumerates a detailed list of reflections with both 2θ and d-spacing values. It narrows infringement to materials whose XRPD pattern includes those specific reflection positions and corresponding d-spacings.

Claim 7 enumerated reflections (from your excerpt)

The claim 7 list is:

5.4897° 2θ, d = 16.09873 Å
8.7494° 2θ, d = 10.10683 Å
11.0426° 2θ, d = 8.01261 Å
16.4521° 2θ, d = 5.38818 Å
16.6518° 2θ, d = 5.32402 Å
17.4975° 2θ, d = 5.06857 Å
18.853° 2θ, d = 4.7071 Å
21.2176° 2θ, d = 4.18756 Å
21.7532° 2θ, d = 4.08564 Å
22.7425° 2θ, d = 3.9101 Å

Scope and litigation leverage

Strength for the patentee: A full list reduces “what peaks count” disputes. It also makes it easier to argue that a polymorph not matching the listed lattice spacings is outside scope.
Strength for the defense: The more numbers a claim lists, the more room exists for challenge on:
- missing peaks,
- peak shifts beyond “about” (though your excerpt lists exact values rather than “about” for claim 7),
- instrument-dependent peak position variation,
- and whether the accused material produces the required reflections under tested conditions.

In practice, claim 7 can become the centerpiece for expert claim charts because it is granular.

What does claim 8 (composition) cover, and how does it interact with formulation patents?

Answer: Claim 8 covers “a composition comprising the crystalline form of Compound I-7 of claim 1.” This is a downstream product claim that can cover solid dosage forms or mixtures, as long as the claimed crystalline form is present.

Typical infringement scenarios under claim 8

tablets/capsules containing the crystalline form as the drug substance;
powder blends where crystalline form persists through formulation;
drug-device combination products only if the crystalline form is present in the composition (scope depends on how the term “composition” is construed in the full patent).

Typical route-to-avoid

use a different polymorph/solvate that does not infringe claim 1;
use a crystalline form that converts after processing into an infringing phase (creates risk);
use an amorphous form (avoid, but only if stable and not converting into the claimed polymorph).

What is the likely patent “landscape” implied by this claim set?

Answer: This claim set signals a crystallization-polymorph strategy where the patent holder seeks to secure exclusive rights over:

a specific XRPD-defined polymorph (possibly the thermodynamically stable or manufacturable form),
an anhydrous variant,
and a basic composition claim for drug product formulation.

Likely adjacent patent families (based on claim pattern, not numbers)

Even without additional documents in your prompt, the claim structure points to common co-existing estates around a single API (Compound I-7):

earlier process/enabling patents (synthesis, intermediates, and general API);
polymorph/solid-state screening patents (often multiple XRPD-defined forms);
salt/solvate patents (if applicable);
formulation patents (if any exist separately) that add excipient systems, particle size, or release profiles;
method-of-use patents (if the molecule has an associated therapeutic use).

For licensing and litigation, the critical question is whether US 12,180,219 is:

an add-on polymorph patent that can be designed around by selecting a different form, or
the dominant solid-state patent that blocks all feasible solid forms.

This is determined by whether the claimed polymorph is the one used in the marketed product and whether credible alternatives exist.

When does this patent expire, and how does exclusivity timing work?

Answer: This excerpt does not provide filing date, priority date, or term adjustments needed to compute expiration. No enforceable timing can be produced from the provided information alone.

What normally drives term in the US for crystalline form patents

earliest non-provisional filing date (20-year term),
potential patent term adjustment (PTA),
possible patent term extension (PTE) tied to regulatory approval (rare for typical crystalline-form patents; depends on whether the patent covers an eligible regulatory review period and the claimed subject matter).

Because no priority or PTA data is supplied, an expiration timeline cannot be stated accurately.

What generic or biosimilar entry risks exist for XRPD-defined polymorph patents?

Answer: The entry risk is highest if an ANDA/505(b)(2) applicant plans to use the same solid-state form as the reference listed drug or a form that converts to the claimed polymorph during storage or manufacturing. Risk drops if the applicant uses a different polymorph/solvate and can demonstrate non-matching XRPD patterns and non-anhydrous status (where claim 6 matters).

Typical ANDA Paragraph IV-style risk profile for crystalline-form patents

If the reference product uses the patented polymorph and the generic uses the same or a closely related solid, the XRPD match often becomes the primary litigated issue.
If the generic uses a different polymorph, defenses typically center on:
- missing peaks,
- shifted peaks outside tolerances,
- differences in full fingerprint (claim 7),
- and anhydrous status.

Litigation leverage of claim 7

Claim 7 tends to be a strong litigation lever because it provides a measurement-rich fingerprint. Defenses also benefit because granular lists can be tested comparatively.

What matters for FDA regulatory status and Orange Book listings of this patent?

Answer: The prompt provides no indication of:

whether US 12,180,219 is listed in the FDA Orange Book,
which drug product it is tied to,
listed expiration date and whether it is tied to a particular NDA/ANDA number,
or whether multiple listed patents exist for the same reference product.

No Orange Book status can be stated from the provided input.

Key Takeaways

US Patent 12,180,219 claims a crystalline form of Compound I-7 defined primarily by an XRPD fingerprint with peaks at about ~5.5, ~8.7, and ~11.0 (claim 1).
Claim scope tightens through dependent claims requiring:
- ~17.5 (claim 2),
- ~22.7 (claim 3),
- both ~17.5 and ~22.7 (claim 4),
- an XRPD pattern “as shown in FIG. 2” (claim 5),
- anhydrous status (claim 6),
- and a full enumerated reflection/d-spacing list (claim 7).
Claim 8 broadens protection to a composition containing the claim 1 crystalline form, raising formulation-level infringement risk if the drug substance used in a product matches the claimed polymorph.
Enforcement and design-around hinge on XRPD measurement comparability and whether an accused solid meets the required peak sets and anhydrous characterization.

FAQs

1) What XRPD peaks define infringement under claim 1?

Claim 1 requires the crystalline form of Compound I-7 to have powder XRPD peaks at about 2θ ~5.5, ~8.7, and ~11.0.

2) Does claim 1 require the absence of other peaks?

The excerpt uses “comprising,” which generally indicates the pattern must include the recited peaks; it does not on its face exclude additional peaks, making measurement matching central rather than “exact peak set only.”

3) Which claim is most restrictive: claim 4, claim 6, or claim 7?

Claim 7 is the most restrictive in fingerprint specificity due to its enumerated reflection/d-spacing list. Claim 6 adds an orthogonal restriction (anhydrous).

4) Can a hydrate or solvate avoid claim 6?

If the accused material is not anhydrous (under relevant characterization), it can avoid claim 6 even if XRPD peaks overlap with the claimed anhydrous form.

5) How does claim 8 expand protection beyond the crystalline solid?

Claim 8 extends protection to any composition that includes the claim 1 crystalline form, so a formulation can infringe if it contains that exact polymorph.

References

No external sources were provided or cited in the prompt.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Sumitomo Pharma Am	GEMTESA	vibegron	TABLET;ORAL	213006-001	Dec 23, 2020		RX	Yes	Yes	12,180,219	⤷ Start Trial	Y	Y			⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Cyprus	1122690	⤷ Start Trial
Denmark	2968269	⤷ Start Trial
European Patent Office	2968269	⤷ Start Trial
European Patent Office	2970927	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 12,180,219